Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10378942 | 1.00 | PYGM (0.53) | PYGMLMNAALBALDH1A1MAPK1 | |
| SCHEMBL24695055 | 1.00 | PYGM (0.53) | PYGMLMNAALBALDH1A1MAPK1 | |
| SCHEMBL13286394 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TK1TSHR | |
| SCHEMBL14596607 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TK1TSHR | |
| SCHEMBL925743 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TK1TSHR | |
| SCHEMBL19657129 | 0.85 | LMNA (0.48) | LMNAALBALDH1A1MAPK1TK1 | |
| SCHEMBL23485 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TK1TSHR | |
| SCHEMBL762579 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TK1TSHR | |
| SCHEMBL22992337 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TK1TSHR | |
| SCHEMBL14421795 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2012115578-A1 | SYNTHESIS OF FLG | MEDIVIR AB (SE) | 2012-08-30 | — | — | WO | disclosed |
| WO-2008118879-A2 | ANTIVIRAL COMPOSITIONS COMPRISING 2 COMPOUNDS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | PYGM 3711/4885LMNA 3687/4885ALB 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.